Bulk Pharmaceutical API Sources for ADVIL PM

Bulk Pharmaceutical API Sources for ADVIL PM

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-25B01712

Bulk Active Pharmaceutical Ingredient (API) Sources for Advil PM

Last updated: February 19, 2026

Advil PM, an over-the-counter (OTC) medication combining ibuprofen and diphenhydramine HCl, relies on a consistent and quality supply of its two Active Pharmaceutical Ingredients (APIs). This analysis identifies potential bulk API manufacturers and relevant considerations for sourcing ibuprofen and diphenhydramine HCl to meet Advil PM production demands.

What are the Bulk API Requirements for Advil PM?

Advil PM's formulation is a combination product. The primary APIs are:

• Ibuprofen: A nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, fever, and inflammation.
  • CAS Number: 15687-27-1
  • Chemical Name: (±)-2-(4-(2-methylpropyl)phenyl)propanoic acid
  • Typical Purity Standard: USP (United States Pharmacopeia) or EP (European Pharmacopoeia) monograph.
  • Dosage in Advil PM: Typically 200 mg per dose.
• Diphenhydramine HCl: An antihistamine with sedative properties, used for its sleep-aid effect.
  • CAS Number: 147-24-0
  • Chemical Name: 2-(diphenylmethoxy)-N,N-dimethylethanamine hydrochloride
  • Typical Purity Standard: USP or EP monograph.
  • Dosage in Advil PM: Typically 38 mg per dose.

The sourcing strategy for these APIs must consider global manufacturing capabilities, regulatory compliance, quality control, and supply chain reliability.

Who are the Key Manufacturers of Ibuprofen API?

Ibuprofen is a widely produced API globally. Major manufacturers are concentrated in Asia, particularly China and India, due to cost advantages and established chemical manufacturing infrastructure.

• Major Manufacturers & Locations:

  • BASF SE: Global chemical company with API manufacturing capabilities, though specific Advil PM API production is not publicly detailed for this entity. Historically a significant player in ibuprofen.
  • IOL Chemicals and Pharmaceuticals Ltd. (India): One of the world's largest producers of ibuprofen API. They have significant capacity and a strong regulatory track record.
  • Granules India Ltd. (India): Another prominent Indian manufacturer of ibuprofen API, serving global markets with USP and EP compliant material.
  • Anqiu Winsun Chemical Co., Ltd. (China): A Chinese manufacturer that supplies ibuprofen API.
  • Shandong Xinhua Pharmaceutical Co., Ltd. (China): A large pharmaceutical enterprise in China producing various APIs, including ibuprofen.
  • Shijiazhuang Donghua Jinlong Chemical Co., Ltd. (China): Another Chinese producer of ibuprofen API.

• Production Capacity & Market Share:

  • The global ibuprofen API market is estimated to be several thousand metric tons annually.
  • Indian manufacturers, such as IOLCP and Granules India, are often cited as holding substantial global market share in ibuprofen API production.
  • Chinese manufacturers collectively represent a significant portion of the global supply.

• Regulatory Compliance: Manufacturers must adhere to current Good Manufacturing Practices (cGMP). Certifications from regulatory bodies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and others are critical. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are also important for market access in Europe.

Who are the Key Manufacturers of Diphenhydramine HCl API?

Diphenhydramine HCl is also a well-established API with multiple manufacturers globally. Similar to ibuprofen, a significant portion of global production is based in Asia.

• Major Manufacturers & Locations:

  • BASF SE: (As above, capabilities exist, specific product line for Advil PM not detailed).
  • Jubilant Pharmova Limited (India): Manufactures diphenhydramine HCl API, compliant with major pharmacopoeial standards.
  • Divi's Laboratories Limited (India): A large custom synthesis and API manufacturer that may produce diphenhydramine HCl.
  • Anqiu Winsun Chemical Co., Ltd. (China): Listed as a producer of diphenhydramine HCl.
  • Shandong Xinhua Pharmaceutical Co., Ltd. (China): Also a producer of diphenhydramine HCl API.
  • Nantong Health Chemical Co., Ltd. (China): A Chinese manufacturer of diphenhydramine HCl.

• Production Capacity & Market Share:

  • The global demand for diphenhydramine HCl API is substantial, driven by its use in various OTC and prescription products, including sleep aids, allergy medications, and motion sickness treatments.
  • Market share data is less granular than for ibuprofen, but India and China are dominant supply regions.

• Regulatory Compliance: Similar to ibuprofen, cGMP compliance and relevant regulatory filings (e.g., Drug Master Files - DMFs) with agencies like the FDA and EMA are essential.

What are the Sourcing Challenges and Considerations?

Sourcing bulk APIs for a widely distributed product like Advil PM involves several critical factors beyond just identifying manufacturers.

• Quality and Compliance:

  • cGMP Audits: Rigorous audits of manufacturing facilities are necessary to ensure consistent cGMP compliance. This includes facility design, process controls, validation, quality control testing, and documentation.
  • Pharmacopoeial Standards: APIs must meet the specifications outlined in relevant pharmacopoeias (USP, EP, JP, etc.). Verification through independent testing is crucial.
  • Impurity Profiles: Manufacturers must control known and potential impurities, including genotoxic impurities, to meet stringent regulatory limits. Detailed impurity profiles and analytical methods must be available.
  • Country of Origin Risk: While cost-effective, sourcing from regions with less robust regulatory oversight can introduce higher supply chain risks. Diversification of sourcing can mitigate this.

• Supply Chain Reliability and Security:

  • Geopolitical Factors: Dependence on single regions or countries can expose the supply chain to disruptions from trade disputes, natural disasters, or political instability.
  • Logistics and Transportation: Efficient and secure transportation of APIs, which can be sensitive to temperature and humidity, is vital. International shipping times and customs clearance processes must be managed.
  • Inventory Management: Maintaining adequate safety stock levels to buffer against lead time variations or unexpected demand spikes is critical.
  • Supplier Diversification: Engaging multiple qualified suppliers for each API, even if at lower volumes initially, provides redundancy and bargaining power.

• Cost and Commercial Terms:

  • Negotiation Power: Large-volume purchases of established APIs like ibuprofen and diphenhydramine HCl offer opportunities for competitive pricing.
  • Contractual Agreements: Long-term supply agreements with clear terms on pricing, delivery schedules, quality specifications, and force majeure clauses are essential.
  • Currency Fluctuations: For international sourcing, currency exchange rates can impact the final landed cost. Hedging strategies may be considered.

• Regulatory Submissions:

  • Drug Master Files (DMFs): API manufacturers should have submitted comprehensive DMFs to regulatory authorities like the FDA. These confidential documents provide detailed information about the API manufacturing process, facilities, and controls.
  • Site Master Files (SMFs): Similar to DMFs, SMFs provide site-specific information for regulatory review.
  • Regulatory Agency Inspections: API suppliers must be prepared for inspections by regulatory bodies such as the FDA, EMA, and others as part of the finished drug product approval and ongoing compliance.

What are the Regulatory Frameworks Governing API Sourcing?

The sourcing and use of APIs for pharmaceutical products are strictly regulated by health authorities worldwide.

• US Food and Drug Administration (FDA):

  • cGMP: 21 CFR Part 210 and 211 mandate Good Manufacturing Practices for finished pharmaceuticals and the APIs used in them.
  • Drug Master Files (DMFs): API manufacturers submit DMFs (Type II for drug substance) to the FDA to support drug product applications.
  • Inspections: The FDA conducts routine pre-approval and routine surveillance inspections of API manufacturing sites, both domestically and internationally.

• European Medicines Agency (EMA) & National Agencies:

  • EudraLex Volume 4 (EU Guidelines for GMP): Similar to FDA's cGMP, these guidelines cover API manufacturing.
  • Certificates of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the relevant European Pharmacopoeia monograph.
  • Inspections: European national competent authorities conduct GMP inspections.

• Other International Bodies:

  • ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provides harmonized guidelines (e.g., ICH Q7 for GMP for APIs) adopted by major regulatory regions.
  • PIC/S: The Pharmaceutical Inspection Co-operation Scheme promotes harmonized GMP standards and quality systems.

• Supplier Qualification Process: A robust supplier qualification program is non-negotiable. This typically involves:

  1. Initial Screening: Review of company background, regulatory status, and product documentation (e.g., Certificates of Analysis, technical data sheets).
  2. Documentation Review: Detailed assessment of DMFs, regulatory approvals, and quality agreements.
  3. On-Site Audit: Comprehensive audit of the manufacturing facility and quality systems by the drug product manufacturer's quality assurance team.
  4. Ongoing Monitoring: Regular review of quality metrics, batch records, and periodic re-audits.

Key Takeaways

• Dual Sourcing Strategy: For both ibuprofen and diphenhydramine HCl, a dual sourcing strategy is recommended to mitigate supply chain risks, leveraging manufacturers in both India and China, while ensuring stringent quality and regulatory compliance.
• Quality Over Cost: While cost is a factor, the paramount consideration is consistent quality and regulatory adherence, verified through thorough supplier audits and documentation review.
• Long-Term Contracts: Securing long-term supply agreements with qualified vendors is essential for price stability and guaranteed supply volumes.
• Regulatory Vigilance: Continuous monitoring of regulatory changes and API supplier compliance is critical to maintain product integrity and market access.

FAQs

1. What is the typical lead time for sourcing bulk Advil PM APIs from Asian manufacturers?

Lead times can range from 8 to 16 weeks for standard orders, not including time for supplier qualification, initial sample testing, and potential customs delays. Urgent or unusually large orders may require longer lead times or premium expedited shipping.

2. Are there significant differences in the quality of ibuprofen API produced in India versus China?

Quality differences are more attributed to individual manufacturers' cGMP compliance and quality systems rather than a general country-wide disparity. Reputable manufacturers in both India and China adhere to stringent USP/EP standards. The key is rigorous supplier qualification and ongoing monitoring.

3. What are the primary risks associated with relying on a single API supplier for Advil PM production?

Single-source reliance exposes production to risks including supply disruptions due to manufacturing issues, natural disasters, geopolitical events, or supplier financial instability. It also limits negotiation leverage on pricing and can impact the ability to adapt to changing demand.

4. How frequently should API supplier audits be conducted?

Routine cGMP audits for established, high-risk API suppliers are typically conducted every 1 to 2 years. However, the frequency can be adjusted based on audit findings, regulatory history, and the criticality of the API to the finished product. A more frequent schedule might be required for new suppliers or those with recent quality issues.

5. What is the role of a Drug Master File (DMF) in API sourcing for Advil PM?

A DMF is a submission to regulatory authorities (like the FDA) by an API manufacturer. It contains confidential, detailed information about the manufacturing, processing, packaging, and storage of the API. Drug product manufacturers can reference the DMF in their own regulatory applications, allowing regulators to review the API information without the API manufacturer having to disclose proprietary details directly to the drug product company. This streamlines the approval process and ensures API quality.

---

Citations

[1] United States Pharmacopeia. (n.d.). USP-NF. U.S. Pharmacopeia. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. EDQM. [3] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General. Retrieved from [FDA website]. [4] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA website]. [5] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4 - Good manufacturing practice. Retrieved from [EMA website]. [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH website].